Novasep, based in Lyon (France), is a group of companies involved in pharmaceutical and biopharmaceutical technologies.
The company emerged as a start-up founded by Roger-Marc Nicoud c. 1995, producing pharmaceuticals, biopharmaceuticals, and purification technologies for food markets.
In 2011, as a result of the financial crisis, the company's debts of 450 million euros had to be restructured; this brought the company's capital through a haircut and debt stake swap into the hands of the American investors Tennenbaum, Silver Point and Pimco.
The founder subsequently left the company and new management was appointed; the headquarters was moved from Pompey in Lorraine to Lyon.
[3] Novasep's Belgium viral vector manufacturing division, Henogen, was sold to Thermo Fisher for €725 million in January 2021.